200 related articles for article (PubMed ID: 11451550)
41. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
Krause BT; Ohlinger R
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
[TBL] [Abstract][Full Text] [Related]
42. Luteal phase support and severe ovarian hyperstimulation syndrome.
McClure N; Leya J; Radwanska E; Rawlins R; Haning RV
Hum Reprod; 1992 Jul; 7(6):758-64. PubMed ID: 1500471
[TBL] [Abstract][Full Text] [Related]
43. GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial.
Fouda UM; Sayed AM; Elshaer HS; Hammad BE; Shaban MM; Elsetohy KA; Youssef MA
J Ovarian Res; 2016 May; 9(1):29. PubMed ID: 27184139
[TBL] [Abstract][Full Text] [Related]
44. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication.
Itskovitz-Eldor J; Kol S; Mannaerts B
Hum Reprod; 2000 Sep; 15(9):1965-8. PubMed ID: 10966996
[TBL] [Abstract][Full Text] [Related]
45. Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women: a prospective randomized trial.
Mai Q; Hu X; Yang G; Luo Y; Huang K; Yuan Y; Zhou C
Am J Obstet Gynecol; 2017 Jan; 216(1):42.e1-42.e10. PubMed ID: 27555316
[TBL] [Abstract][Full Text] [Related]
46. The benefit of individualized low-dose hCG support for high responders in GnRHa-triggered IVF/ICSI cycles.
Huang CY; Shieh ML; Li HY
J Chin Med Assoc; 2016 Jul; 79(7):387-93. PubMed ID: 27147462
[TBL] [Abstract][Full Text] [Related]
47. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
[TBL] [Abstract][Full Text] [Related]
48. 'Prolonged coasting': an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization.
Sher G; Zouves C; Feinman M; Maassarani G
Hum Reprod; 1995 Dec; 10(12):3107-9. PubMed ID: 8822423
[TBL] [Abstract][Full Text] [Related]
49. Embryo freezing for preventing ovarian hyperstimulation syndrome.
D'Angelo A; Amso N
Cochrane Database Syst Rev; 2007 Jul; (3):CD002806. PubMed ID: 17636707
[TBL] [Abstract][Full Text] [Related]
50. [Research on the protocol of limited ovarian stimulation to prevent ovarian hyperstimulation syndrome].
Zhu YM; Gao HJ; He RH; Huang HF
Zhonghua Fu Chan Ke Za Zhi; 2006 Nov; 41(11):740-4. PubMed ID: 17327030
[TBL] [Abstract][Full Text] [Related]
51. Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study.
Gokmen O; Ugur M; Ekin M; Keles G; Turan C; Oral H
Eur J Obstet Gynecol Reprod Biol; 2001 Jun; 96(2):187-92. PubMed ID: 11384805
[TBL] [Abstract][Full Text] [Related]
52. Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support.
Castillo JC; Dolz M; Bienvenido E; Abad L; Casañ EM; Bonilla-Musoles F
Reprod Biomed Online; 2010 Feb; 20(2):175-81. PubMed ID: 20113955
[TBL] [Abstract][Full Text] [Related]
53. Prevention of severe ovarian hyperstimulation by coasting.
Dhont M; Van der Straeten F; De Sutter P
Fertil Steril; 1998 Nov; 70(5):847-50. PubMed ID: 9806565
[TBL] [Abstract][Full Text] [Related]
54. Prevention of severe ovarian hyperstimulation syndrome (OHSS) in IVF patients by steroidal ovarian suppression--a prospective randomized study.
Schwärzler P; Abendstein BJ; Klingler A; Kreuzer E; Rjosk HK
Hum Fertil (Camb); 2003 Aug; 6(3):125-9. PubMed ID: 12960445
[TBL] [Abstract][Full Text] [Related]
55. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study.
Bellver J; Muñoz EA; Ballesteros A; Soares SR; Bosch E; Simón C; Pellicer A; Remohí J
Hum Reprod; 2003 Nov; 18(11):2283-8. PubMed ID: 14585874
[TBL] [Abstract][Full Text] [Related]
56. Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome.
Youssef MA; Al-Inany HG; Evers JL; Aboulghar M
Cochrane Database Syst Rev; 2011 Feb; (2):CD001302. PubMed ID: 21328249
[TBL] [Abstract][Full Text] [Related]
57. Preliminary experience with steroidal ovarian suppression for prevention of severe ovarian hyperstimulation syndrome in IVF patients.
Rjosk HK; Abendstein BJ; Kreuzer E; Schwärzler P
Hum Fertil (Camb); 2001; 4(4):246-8. PubMed ID: 11719720
[TBL] [Abstract][Full Text] [Related]
58. In-vitro fertilization and the ovarian hyperstimulation syndrome.
MacDougall MJ; Tan SL; Jacobs HS
Hum Reprod; 1992 May; 7(5):597-600. PubMed ID: 1639974
[TBL] [Abstract][Full Text] [Related]
59. [Value of serum inhibin B measurement in predicting ovarian response in controlled ovarian hyperstimulation for in vitro fertilization cycle].
Chen Y; Yu Q; Zhang YW; He FF; Sun ZY
Zhonghua Fu Chan Ke Za Zhi; 2006 Jun; 41(6):368-71. PubMed ID: 16831355
[TBL] [Abstract][Full Text] [Related]
60. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
